Sacubitril/valsartan could exert heterogeneous remedy impact in coronary heart failure with preserved ejection fraction (HFpEF). We aimed to develop a machine studying (ML)-based mannequin to individualize the cardiovascular advantages of sacubitril/valsartan. Utilizing information from 4161 sufferers within the PARAGON-HF trial, we constructed a phenomap primarily based on 53 baseline traits, using the Gower distance metric. A semiparametric proportional charges methodology was utilized inside every affected person’s 20% phenotypic neighborhood to calculate individualized price ratios (RRs) for remedy results of sacubitril/valsartan versus valsartan on the composite end result of cardiovascular loss of life or whole hospitalizations for coronary heart failure. This metric, the phenotype-specific response rating (PRS), quantifies remedy profit, with destructive PRS values indicating better profit. The median PRS was −0.62 (interquartile vary: −1.21 to 0.05), with out important general remedy profit noticed in the entire inhabitants (RR, 0.90; 95% CI, 0.77–1.06). Nevertheless, 70.8% of sufferers had a PRS ≤ 0, displaying an 18% threat discount with sacubitril/valsartan (RR, 0.82; 95% CI, 0.69–0.98). Notably, 57.6% of males and 70.2% of sufferers with LVEF > 57% had a PRS ≤ 0, suggesting profit in subgroups sometimes thought of much less responsive. To help scientific use, we developed the PARAGUIDE precision device utilizing 16 available variables. The mannequin was internally validated by way of repeated 4-fold cross-validation and externally validated in sufferers from the PARADIGM-HF trial. We developed an ML-driven mannequin to foretell the individualized remedy results of sacubitril/valsartan in contrast with valsartan in sufferers with HFpEF. By figuring out potential responders, the PARAGUIDE precision device advances precision medication past conventional subgroup analyses.
